{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:05:05Z","timestamp":1777637105912,"version":"3.51.4"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Antipsychotic monotherapy is considered the standard for schizophrenia treatment. However, many patients with schizophrenia and other psychotic disorders receive antipsychotic polypharmacy (APP). This can be associated with increased adverse effects, drug interactions, and treatment costs. This review aims to synthesize evidence on the prevalence of APP in the Middle East, North Africa, Turkey, and the Eastern Mediterranean (MENAT\/EMRO) countries. Eight databases were systematically searched for studies published up to February 2026 that reported APP prevalence among patients with schizophrenia and psychotic disorders in MENAT and EMRO countries. The methodological quality was assessed using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist, while the overall certainty of evidence was evaluated using GRADE conceptual approach (Grading of Recommendations Assessment, Development and Evaluation). The pooled prevalence was estimated using random-effects meta-analysis, and statistical heterogeneity was assessed using tau-squared (\u03c4\u00b2) and I\u00b2 statistic. Potential sources of heterogeneity were explored through subgroup and meta-regression analyses, and publication bias was assessed using funnel plots and Egger\u2019s tests. Seventeen studies with 6,053 individuals with schizophrenia and other psychotic disorders were included. The pooled prevalence of APP was 50% (95% CI: 37%\u201362%), with substantial heterogeneity (I\u00b2 = 98.4%), and was commonly associated with second-generation antipsychotics. Evidence linking APP to specific demographic and clinical variables was limited to a few studies, which found APP associated with higher number of hospitalizations. A pooled prevalence across nine of the APP studies revealed that only 12% (95% CI: 8% to 18%) were receiving clozapine. APP is highly prevalent in MENAT\/EMRO countries. Given the potential harms of polypharmacy and the limited evidence supporting it, we recommend efforts to reduce APP and increase clozapine utilization among eligible patients. Evidence-based guidelines, clinician training, and improved clozapine accessibility are crucial to optimizing schizophrenia management in the region.<\/jats:p>","DOI":"10.3389\/fpsyt.2026.1792876","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:02:24Z","timestamp":1777442544000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of antipsychotic polypharmacy in patients with schizophrenia and other psychotic disorders in the MENAT and EMRO countries: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Mohammed A.","family":"Alhassan","sequence":"first","affiliation":[{"name":"Department of Medical Specialties, College of Medicine, Majmaah University","place":["Al Majmaah, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed A.","family":"Alarabi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, College of Medicine, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waled M.","family":"Albalawi","sequence":"additional","affiliation":[{"name":"King Salman Armed Forces Hospital","place":["Tabuk, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thenuwara Arachchige Omila Kasun","family":"Meetiyagoda","sequence":"additional","affiliation":[{"name":"Saitama University","place":["Saitama, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anum","family":"Nisar","sequence":"additional","affiliation":[{"name":"Institute of Population Health, University of Liverpool","place":["Liverpool, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wondim","family":"Ayenew","sequence":"additional","affiliation":[{"name":"Department of Social and Administrative Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar","place":["Gondar, Ethiopia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatimah A","family":"Shehab","sequence":"additional","affiliation":[{"name":"King Saud Medical City","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[{"name":"Schizophrenia Division, Centre for Addiction and Mental Health (CAMH)","place":["Toronto, ON, Canada"]},{"name":"Department of Psychiatry, University of Toronto","place":["Toronto, ON, Canada"]},{"name":"Institute of Medical Sciences, University of Toronto","place":["Toronto, ON, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"B1","volume-title":"Diagnostic and statistical manual of mental disorders: DSM-5","year":"2013"},{"key":"B2","volume-title":"Schizophrenia","year":"2025"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1808803","article-title":"Schizophrenia","volume":"381","author":"Marder","year":"2019","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2025.104496","article-title":"Trends and disparities in schizophrenia related mortality in the United States: An analysis of CDC WONDER database, 1999\u20132020","volume":"108","author":"Yadav","year":"2025","journal-title":"Asian J Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1176\/appi.focus.20190047","article-title":"Antipsychotic polypharmacy","volume":"18","author":"Foster","year":"2020","journal-title":"FOC"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: Treatment response and resistance in psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"AJP"},{"key":"B7","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"American psychiatric association practice guideline for the treatment of patients with schizophrenia","volume":"177","year":"2020","journal-title":"Am J Psychiatry"},{"key":"B8","volume-title":"Psychosis and schizophrenia in adults: treatment and management","year":"2014"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/0004867416641195","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders","volume":"50","author":"Galletly","year":"2016","journal-title":"Aust N Z J Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The american psychiatric association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"AJP"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.euroneuro.2025.08.580","article-title":"Antipsychotic polypharmacy in patients with schizophrenia between 1999 and 2024 in Denmark: Prevalence, time trends, and combinations","volume":"100","author":"H\u00f8jlund","year":"2025","journal-title":"Eur Neuropsychopharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241986","article-title":"Patterns of prescription of antipsychotics in Qatar","volume":"15","author":"Ouanes","year":"2020","journal-title":"PloS One"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2024.07.035","article-title":"Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data","volume":"272","author":"Lochmann Van Bennekom","year":"2024","journal-title":"Schizophr Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2019.10.022","article-title":"Adverse outcomes of polypharmacy in older people: Systematic review of reviews","volume":"21","author":"Davies","year":"2020","journal-title":"J Am Med Directors Assoc"},{"key":"B15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","volume":"17","author":"Masnoon","year":"2017","journal-title":"BMC Geriatr"},{"key":"B16","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1186\/s12877-022-03279-x","article-title":"Prevalence and factors associated with polypharmacy: a systematic review and meta-analysis","volume":"22","author":"Delara","year":"2022","journal-title":"BMC Geriatr"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/22423982.2023.2218654","article-title":"Nationwide study on antipsychotic polypharmacy among forensic psychiatric patients","volume":"82","author":"Lassen","year":"2023","journal-title":"Int J Circumpolar Health"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/XEB.0000000000000054","article-title":"Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data","volume":"13","author":"Munn","year":"2015","journal-title":"Int J Evidence-Based Healthcare"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.09.018","article-title":"GRADE Guidelines 30: the GRADE approach to assessing the certainty of modeled evidence-An overview in the context of health decision-making","volume":"129","author":"Brozek","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S0924-9338(13)75947-9","article-title":"731 \u2013 Antipsychotic prescribing pattern in Arab patients with schizophrenia","volume":"28","author":"Amr","year":"2013","journal-title":"Eur Psychiatr"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-025-04228-4","article-title":"Antipsychotic treatment patterns and predictors of polypharmacy in psychotic disorders: 20-year real-world data from a tertiary center","author":"Da\u011fdemir","year":"2025","journal-title":"Ir J Med Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2007.12.031","article-title":"Antipsychotic prescriptions in a university hospital outpatient population in Turkey: A retrospective database analysis, 2005\u20132006","volume":"32","author":"Atik","year":"2008","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.59049\/2790-0231.1137","article-title":"Prevalence and factors associated with polypharmacy among patients treated for psychiatric disorders in Palestine","volume":"8","author":"Hattab","year":"2023","journal-title":"Palestinian Med Pharm J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2020.102063","article-title":"Multiple antipsychotics use in patients with schizophrenia: Why do we use it, what are the results from patient follow-ups","volume":"52","author":"Civan Kahve","year":"2020","journal-title":"Asian J Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2174\/1745017901713010092","article-title":"Antipsychotic use pattern in schizophrenia outpatients: Correlates of polypharmacy","volume":"13","author":"Yazici","year":"2017","journal-title":"CPEMH"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(24)00314-6","article-title":"Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis","volume":"11","author":"H\u00f8jlund","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16113","article-title":"The prevalence of polypharmacy in older Europeans: A multi\u2010national database study of general practitioner prescribing","volume":"90","author":"Bennie","year":"2024","journal-title":"Brit J Clin Pharma"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1186\/s41256-023-00311-4","article-title":"Prevalence and trends of polypharmacy in U.S. adults, 1999\u20132018","volume":"8","author":"Wang","year":"2023","journal-title":"Glob Health Res Policy"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyab046","article-title":"Antipsychotic polypharmacy among patients with schizophrenia in Africa: A systematic review and meta-analysis","volume":"24","author":"Ayenew","year":"2021","journal-title":"Int J Neuropsychopharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2020.102022","article-title":"Frequency, reasons, and factors associated with antipsychotic polypharmacy in schizophrenia: A retrospective chart review in a tertiary hospital in India","volume":"51","author":"Shenoy","year":"2020","journal-title":"Asian J Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000040897","article-title":"The factors associated with clozapine polypharmacy for schizophrenia patients discharged from a large public psychiatric hospital in Taiwan, 2006\u20132021","volume":"103","author":"Shih","year":"2024","journal-title":"Medicine"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1177\/0004867418805559","article-title":"Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan","volume":"52","author":"Qiu","year":"2018","journal-title":"Aust N Z J Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1177\/1039856214546672","article-title":"Prevalence and nature of antipsychotic polypharmacy among inpatients with schizophrenia spectrum disorders at an Australian mental health service","volume":"22","author":"John","year":"2014","journal-title":"Australas Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12467","article-title":"Prevalence of polypharmacy and factors impacting psychotropic prescribing patterns in women of childbearing potential at inpatient mental health services in Qatar","volume":"44","author":"Elbakary","year":"2024","journal-title":"Neuropsychopharm Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2174\/0929867043456070","article-title":"A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation","volume":"11","author":"Stahl","year":"2004","journal-title":"Curr Med Chem"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13742","article-title":"Prevalence and predictors of polypharmacy in Jordanian hospitalised patients: A cross\u2010sectional study","volume":"75","author":"Abu Farha","year":"2021","journal-title":"Int J Clin Pract"},{"key":"B38","doi-asserted-by":"publisher","first-page":"448","DOI":"10.47626\/1516-4446-2023-3126","article-title":"Treatment resistance in schizophrenia: a meta-analysis of prevalence and correlates","volume":"45","author":"Diniz","year":"2023","journal-title":"Braz J Psychiatry"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2018.12.011","article-title":"A qualitative exploration of clozapine prescribing and monitoring practices in the Arabian Gulf countries","volume":"39","author":"Ismail","year":"2019","journal-title":"Asian J Psychiatry"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0328495","article-title":"Declines and pronounced state-level variation in clozapine use among Medicare patients","volume":"20","author":"Cavanah","year":"2025","journal-title":"PloS One"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13280","article-title":"An evaluation of the variation and underuse of clozapine in the United Kingdom","volume":"143","author":"Whiskey","year":"2021","journal-title":"Acta Psychiatr Scand"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2012.03.003","article-title":"Geographical and temporal variations in clozapine prescription for schizophrenia","volume":"22","author":"Nielsen","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201300180","article-title":"Geographic and clinical variation in clozapine use in the United States","volume":"65","author":"Stroup","year":"2014","journal-title":"PS"},{"key":"B44","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/acps.12742","article-title":"International trends in clozapine use: a study in 17 countries","volume":"136","author":"Bachmann","year":"2017","journal-title":"Acta Psychiatr Scand"},{"key":"B45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3371\/csrp.lawy.012513","article-title":"Underprescribing of clozapine and unexplained variation in use across hospitals and regions in the Canadian province of Qu\u00e9bec","volume":"7","author":"Latimer","year":"2013","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2026.101602","article-title":"Global trends in clozapine utilisation between 2014 and 2024: a longitudinal epidemiological study with data from 75 countries","volume":"63","author":"Fitzgerald","year":"2026","journal-title":"Lancet Regional Health - Europe"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.111.105833","article-title":"Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation","volume":"201","author":"Howes","year":"2012","journal-title":"Br J Psychiatry"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1017\/ipm.2018.47","article-title":"Treatment resistant schizophrenia - review and a call to action","volume":"36","author":"Lally","year":"2019","journal-title":"Ir J Psychol Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40737-022-00287-3","article-title":"Exploration of the barriers to clozapine prescribing in patients with treatment-resistant schizophrenia: A qualitative study","volume":"10","author":"Rezaie","year":"2023","journal-title":"J Psychosoc Rehabil Ment Health"},{"key":"B50","doi-asserted-by":"publisher","first-page":"4","DOI":"10.63050\/jpps.20.04.283","article-title":"Barriers to clozapine use in treatment-refractory population in karachi, Pakistan","volume":"20","author":"Shad","year":"2023","journal-title":"J Pak Psychiatr Soc"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2025.104698","article-title":"A systematic review of clozapine in the Arab world: Patterns of use, barriers and facilitators in clinical practice","volume":"112","author":"Al-Huseini","year":"2025","journal-title":"Asian J Psychiatry"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201700162","article-title":"Addressing barriers to clozapine underutilization: A national effort","volume":"69","author":"Kelly","year":"2018","journal-title":"PS"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.112.114777","article-title":"Clinician hesitation prior to clozapine initiation: Is it justifiable","volume":"201","author":"Patel","year":"2012","journal-title":"Br J Psychiatry"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00182","article-title":"The Arab region\u2019s contribution to global mental health research (2009\u20132018): A bibliometric analysis","volume":"11","author":"Zeinoun","year":"2020","journal-title":"Front Psychiatry"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1590167","article-title":"Evaluation of drug interactions in outpatients taking antipsychotic medications","volume":"16","author":"Alsfouk","year":"2025","journal-title":"Front Pharmacol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"64","DOI":"10.12816\/0058767","article-title":"Prescribing clozapine in the MENA region: The perspective and practice of psychiatrists","volume":"32","author":"El Hayek","year":"2021","journal-title":"AJP"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo2044","article-title":"A meta-analysis suggests that tACS improves cognition in healthy, aging, and psychiatric populations","volume":"15","author":"Grover","year":"2023","journal-title":"Sci Transl Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2023.09.002","article-title":"An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance","volume":"268","author":"Sagud","year":"2024","journal-title":"Schizophr Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1177\/03000605251332443","article-title":"Description of schizophrenia treatment outcomes in Saudi Arabia: A preliminary pilot investigation","volume":"53","author":"AlDosari","year":"2025","journal-title":"J Int Med Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/NDT.S78788","article-title":"Use of second-generation antipsychotics in acute inpatient management of schizophrenia in the Middle East","volume":"9","author":"Alkhadhari","year":"2015","journal-title":"NDT"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.5455\/bcp.20120419124219","article-title":"Comparison of polypharmacy in schizophrenia and other psychotic disorders in outpatient and inpatient treatment periods: A naturalistic one year follow-up study","volume":"22","author":"Karadag","year":"2012","journal-title":"Klinik Psikofarmakoloji B\u00fclteni-Bulletin Clin Psychopharmacol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4314\/tjpr.v17i2.20","article-title":"Antipsychotic prescription patterns and treatment costs of schizophrenia in northwestern Pakistan: A one-year observational study","volume":"17","author":"Khan","year":"2018","journal-title":"Trop J Pharm Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/jphsr\/rmac019","article-title":"Evaluation of antipsychotic medication adherence and its relation to negative and positive psychiatric symptoms","volume":"13","author":"Khdour","year":"2022","journal-title":"J Pharm Health Serv Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"653","DOI":"10.12669\/pjms.35.3.136","article-title":"Changing trends in anti-psychotic prescription pattern in Pakistan: Anti-psychotic prescription pattern in Pakistan","volume":"35","author":"Malik","year":"2019","journal-title":"Pak J Med Sci"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-179","article-title":"Conformance to schizophrenia treatment guidelines in North West-Bank, Palestine: Focus on antipsychotic dosing and polytherapy","volume":"13","author":"Sweileh","year":"2013","journal-title":"BMC Psychiatry"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2007.01.001","article-title":"Sexual dysfunction in patients with schizophrenia on antipsychotic medication","volume":"22","author":"\u00dc\u00e7ok","year":"2007","journal-title":"Eur Psychiatr"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.12676","article-title":"Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries: Fourth survey of Research on Asian Prescription Patterns on antipsychotics","volume":"72","author":"Yang","year":"2018","journal-title":"Psychiatry Clin Neurosci"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1080\/13651500310003327","article-title":"Antipsychotic drug use pattern for patients with schizophrenia in an outpatient clinic in Turkey: A retrospective study","volume":"8","author":"Yildiz","year":"2004","journal-title":"Int J Psychiatry Clin Pract"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1792876\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:02:27Z","timestamp":1777442547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1792876\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":68,"alternative-id":["10.3389\/fpsyt.2026.1792876"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1792876","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"article-number":"1792876"}}